A new era in antibacterial technology - from prototype to technical and clinical validation

Reference number 2015-02069
Coordinator CytaCoat Aktiebolag - CytaCoat AB, Karolinska Science Park
Funding from Vinnova SEK 3 050 000
Project duration June 2015 - August 2017
Status Completed

Purpose and goal

CytaCoat AB has developed a unique bacterial resistant surface coating technology that inhibits the growth of all tested bacterial types, including multiresistant strains (e.g. MRSA). It can be used on medical devices where bacterial growth is a significant clinical problem. The project aimed to generate a first proof-of-concept in humans to enable development towards a first commercial application of the CytaCoat technology on a medical device. The project was very successful in this respect and forms a strong basis for commercialising the technology.

Expected results and effects

In a study of 48 individuals an inhibition in bacterial growth of > 10log 5 on coatade prongs compared to uncoated prongs was achievd (p<0,0001), a strong inhibition of bacterial growth. as a result cytacoat is currently proceeding with concrete discussions with an identified potential commercial partner. the result is expected to increase chances of identifying potential partners for commercialisation of the technology on other medical devices associated with health care associated infections.>

Planned approach and implementation

A first-in-human study on 24+24 healthy adult volunteers was conducted by the Neonatal unit at Karolinska University Hospital. Subjects carried a coated or uncoated nasal prong for 18 hours and evaluated with a bacterial endpoint to measure the antibacterial effect. The project included technical development for application of CytaCoat surface on nasal prongs made of silicone, biocompabilitystudies, prestudy-, execution-, and poststudy- phases of the clinical study, business development and IP

The project description has been provided by the project members themselves and the text has not been looked at by our editors.